GKB Ophthalmics working capital

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY23Mar 2023
161.78×
64.20×
139.21×
86.77×
−6.68×
0.56×
0.40×
1.04×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

GKB₹60.50

GKB Ophthalmics Limited

· Pharma & Health
₹ CrorePeersFABTECHLAXMIDENTLTARSONSFISCHERMcap ₹30.5 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
Inventory Days (DIO)161.78
Receivable Days (DSO)64.20
Payable Days (DPO)139.21
Cash Conversion Cycle (days)86.77
Working Capital Turnover-6.68
Asset Turnover0.56
Cash Conversion (CFO/Net Income)0.40
CFO/EBITDA1.04
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY23 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.